Investors are not enthusiastic about Pfizer’s reportThe American multinational pharmaceutical corporation Pfizer (PFE) published its financial results report for the fourth quarter of 2021. The company’s shares immediately reacted with a decrease of 6%.

In addition to figures below analysts’ expectations, the corporation gave a forecast for 2022, which also turned out to be not as rosy as expected. In 2022, Pfizer is forecasting earnings in the range of $98 to $102 billion and earnings per share of $6.35 to $6.65. Revenues from sales of the Comirnaty vaccine are expected to be in the region of $32 billion.

The published forecasts are alarming investors, making them doubt the cloudless future of the corporation after the end of the pandemic. It is also worth noting the start of clinical trials of a vaccine against the Omicron strain, which, if successful, will significantly strengthen Pfizer’s position in the market.